There are currently 123 ongoing clinical trials involving Geographic Atrophy
Of the 123 trials,63 trials are in Phase II
Furthermore, 43 trials are in Phase III
The global pharmaceutical industry is steadily developing new drugs for Geographic Atrophy, an ophthalmology indication. The largest number of ongoing clinical trials for Geographic Atrophy is conducted in North America. Europe and Asia-Pacific are among some of the other prominent regions engaged in Geographic Atrophy-related drug trials.
Gyroscope Therapeutics Holdings Ltd: The leading ongoing Geographic Atrophy related clinical trial sponsor
Gyroscope Therapeutics Holdings Ltd is the top sponsor for Geographic Atrophy-related ongoing clinical trials.
Genentech USA Inc, and NGM Biopharmaceuticals Inc are among other notable clinical trial sponsors involved in Geographic Atrophy. A clinical trial sponsor can be a Company, Government, Individual, or Institution.
United States of America
China
Switzerland
United States of America
United States of America
United States of America
United States of America
Germany
France
Switzerland
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer